Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NASDAQ | Common Stock
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection.
It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio.
The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019.
Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 4, 24 | -0.37 Increased by +63.00% | -0.56 Increased by +33.93% |
| Aug 12, 24 | -0.56 Increased by +5.08% | -0.53 Decreased by -5.66% |
| May 15, 24 | -0.75 Decreased by -435.71% | -1.09 Increased by +31.19% |
| Mar 5, 24 | -0.84 Decreased by -281.82% | -1.07 Increased by +21.50% |
| Oct 31, 23 | -1.00 Decreased by -426.32% | -1.12 Increased by +10.71% |
| Aug 14, 23 | -0.59 Decreased by -145.83% | -1.91 Increased by +69.11% |
| Apr 20, 23 | -0.14 Increased by +26.32% | -0.13 Decreased by -7.69% |
| Feb 23, 23 | -0.22 Increased by +18.52% | -0.12 Decreased by -83.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by -100.00% | -2.87 M Increased by +10.72% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 1.28 M Decreased by -31.01% | -2.94 M Decreased by -98.38% | Decreased by -229.87% Decreased by -187.57% |
| Mar 31, 24 | 1.68 M Increased by +231.42% | -3.26 M Increased by +32.16% | Decreased by -194.45% Increased by +79.53% |
| Dec 31, 23 | 1.31 M Increased by +486.16% | -3.81 M Increased by +33.67% | Decreased by -290.18% Increased by +88.68% |
| Sep 30, 23 | 1.24 M Increased by +1.60 K% | -3.22 M Increased by +39.76% | Decreased by -259.60% Increased by +96.45% |
| Jun 30, 23 | 1.85 M Increased by +N/A% | -1.48 M Increased by +72.78% | Decreased by -79.94% Decreased by N/A% |
| Mar 31, 23 | 506.00 K Increased by +N/A% | -4.81 M Decreased by -11.63% | Decreased by -950.00% Decreased by N/A% |
| Dec 31, 22 | 224.00 K Increased by +N/A% | -5.74 M Decreased by -38.24% | Decreased by -2.56 K% Decreased by N/A% |